Omeros Corporation
OMER
Rank in Stocks
#7663
Omeros Corporation is a biopharmaceutical firm with commercialized products,... Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Share Price
$17.55
Last synced: 2026-11-09
Market Cap
$1.27B
Change (1 day)
3.72%
Change (1 year)
154.72%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Omeros Corporation (OMER)
Category
Healthcare
Operating Margin for Omeros Corporation (OMER)
Operating Margin as of November 2026 TTM: -189.53%
According to Omeros Corporation's latest financial reports, its current operating margin (TTM) is -189.53%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Omeros Corporation from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -189.53% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -56.69% | -84.91% |
| 2018 | -375.73% | 454.91% |
| 2017 | -67.71% | -48.08% |
| 2016 | -130.42% | -75.27% |
| 2015 | -527.34% | -95.94% |
| 2014 | -12,988.50% | 311.39% |
| 2013 | -3,157.25% | 415.47% |
| 2012 | -612.50% | 1.09% |
| 2011 | -605.88% | -57.64% |
| 2010 | -1,430.21% | -0.51% |
| 2009 | -1,437.53% | -31.42% |
| 2008 | -2,096.15% | 65.22% |
| 2007 | -1,268.69% | -89.41% |
| 2006 | -11,976.50% | 0.00% |
| 2005 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.20% |
US
|
|
| -149.01% | -99.21% |
US
|
|
| 25.57% | -100.13% |
AU
|
|
| 31.23% | -100.16% |
BE
|
|
| 29.35% | -100.15% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Omeros Corporation's operating margin
What is Omeros Corporation's operating margin?
Omeros Corporation's operating margin is -189.53%, as of Nov 2026.
What was Omeros Corporation's operating margin in 2025?
In 2025, Omeros Corporation's operating margin was 0.00%, compared with 0.00% in 2024.
How has Omeros Corporation's operating margin changed since 2020?
From 2020 to 2025, Omeros Corporation's operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Omeros Corporation's operating margin compare with similar companies?
Omeros Corporation's operating margin (-189.53%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.